Equities Analysts Offer Predictions for FDMT FY2024 Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Equities researchers at Leerink Partnrs cut their FY2024 earnings estimates for 4D Molecular Therapeutics in a research note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($2.95) per share for the year, down from their prior estimate of ($2.84). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.81) per share. Leerink Partnrs also issued estimates for 4D Molecular Therapeutics’ Q4 2024 earnings at ($0.86) EPS and FY2025 earnings at ($3.76) EPS.

FDMT has been the subject of a number of other reports. Cantor Fitzgerald cut 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. Leerink Partners reaffirmed an “outperform” rating and set a $36.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. HC Wainwright restated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday. Chardan Capital reiterated a “buy” rating and issued a $39.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday. Finally, Royal Bank of Canada reduced their price objective on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Thursday. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, 4D Molecular Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $47.00.

4D Molecular Therapeutics Price Performance

4D Molecular Therapeutics stock opened at $8.83 on Monday. The company’s 50-day moving average is $10.30 and its 200-day moving average is $17.03. The firm has a market capitalization of $408.21 million, a PE ratio of -3.10 and a beta of 2.82. 4D Molecular Therapeutics has a fifty-two week low of $7.32 and a fifty-two week high of $36.25.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in FDMT. Healthcare of Ontario Pension Plan Trust Fund raised its holdings in 4D Molecular Therapeutics by 10.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 706,000 shares of the company’s stock valued at $14,819,000 after acquiring an additional 65,000 shares in the last quarter. Kennedy Capital Management LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 1st quarter valued at $4,358,000. Sofinnova Investments Inc. raised its holdings in shares of 4D Molecular Therapeutics by 36.8% during the 2nd quarter. Sofinnova Investments Inc. now owns 271,155 shares of the company’s stock worth $5,692,000 after buying an additional 72,969 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its stake in 4D Molecular Therapeutics by 702.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock valued at $110,000 after buying an additional 3,026 shares in the last quarter. Finally, Novo Holdings A S grew its position in 4D Molecular Therapeutics by 7.1% in the third quarter. Novo Holdings A S now owns 1,500,000 shares of the company’s stock valued at $16,215,000 after acquiring an additional 100,000 shares during the last quarter. 99.27% of the stock is owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.